Skip to content
Aminoscope
Head-to-head

Inositol vs Metformin

The PCOS decision most often made without a clinician on one side and with one on the other — and the guideline is more specific than either camp usually admits.

By Julian RothResearch & dataUpdated October 2026

Short answer

Inositol and metformin both have human clinical data, so the deciding factor is what you want them for. Inositol suits someone focused on PCOS, insulin sensitivity, fertility and anxiety, while metformin is aimed at longevity, healthspan and metabolic aging. On access, inositol is sold over the counter as a supplement, while metformin is a prescription drug.

Inositol

Myo-inositol, D-chiro-inositol

Clinical data

Improves menstrual-cycle regularity in pooled PCOS trials, but the 2023 international guideline graded the evidence very low certainty — live birth is unproven and the 40:1 ratio is unvalidated in humans.

Full Inositol evidence review

Metformin

Clinical data

An approved diabetes drug with an intriguing longevity hypothesis — but the dedicated aging trial (TAME) is still pending; longevity in healthy people is unproven.

Full Metformin evidence review

Inositol vs Metformin: head to head

FDA status / approved use

Inositol

Sold as a dietary supplement; not FDA-approved for PCOS or any other condition

Metformin

Decades-old diabetes drug; taking it for longevity is off-label and unproven
Marketed for

Inositol

PCOS, insulin sensitivity, fertility, anxiety

Metformin

Longevity, healthspan, metabolic aging
Outcome areas

Inositol

Female hormones / fertility / PCOS; Blood sugar / insulin sensitivity; Mood / anxiety / stress

Metformin

Longevity / lifespan; Blood sugar / insulin sensitivity
Evidence grade

Inositol

Clinical data

Metformin

Clinical data
How it works

Inositol

Forms second messengers in insulin signaling; may improve insulin sensitivity

Metformin

Activates AMPK and reduces mTOR signaling, nutrient-sensing pathways tied to aging
Route and dosing

Inositol

Oral, 2 g myo-inositol twice daily in PCOS trials

Metformin

Not established
Headline human result

Inositol

1.79 times the chance of a regular menstrual cycle vs placebo in a 2023 meta-analysis of 26 trials (1,691 women)

Metformin

Observational only: diabetics on metformin survived as long as matched non-diabetics; the TAME outcome trial has not reported
Strongest evidence

Inositol

Guideline systematic review, JCEM 2024Inositol evidence reviewPubMed 38163998

Metformin

MILES/TAME rationale 2014Metformin evidence reviewPubMed 25041462
Key safety signal

Inositol

Nausea, gas, bloating and loose stools, mainly at higher doses

Metformin

Not established
How it is obtained

Inositol

Over the counter as a dietary supplement

Metformin

Prescription drug

marks a row where the two differ. “Not established” marks a cell the available evidence does not answer. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.

Clinical data:
Tested in humans — but investigational, discontinued, or proven only on a surrogate marker (not the marketed outcome).

Our verdict

For cycle regularity the gap is smaller than the prescription-versus-supplement framing suggests: a meta-analysis of 26 randomized trials in 1,691 women found inositol raised the chance of a regular menstrual cycle by a factor of 1.79 versus placebo and was non-inferior to metformin on that outcome, with fewer gastrointestinal side effects. The certainty is the catch. The systematic review behind the 2023 international PCOS guideline read 30 trials in 2,230 participants, called the evidence limited and inconclusive, graded the inositol recommendation very low certainty, and preferred metformin where hirsutism and central adiposity are the concern. Live birth remains genuinely uncertain for inositol on Cochrane's reading of 13 trials. Metformin is also sold separately as a longevity drug, which is a different and still-unproven claim — TAME has not reported.

Inositol fits if

Cycle regularity is the goal, tolerability matters to you, and you accept a guideline grading of very low certainty on a compound you can buy without a prescription.

Metformin fits if

Hirsutism or central adiposity is the concern, or you want the option with guideline preference and an approved-drug evidence base — and you have a clinician to prescribe and monitor it.

Inositol vs Metformin: common questions

Which has stronger human evidence, inositol or metformin?
Neither clearly. Both have human clinical data. The key source for inositol is Guideline systematic review, JCEM 2024; for metformin, it is MILES/TAME rationale 2014.
What results have inositol and metformin shown in people?
The headline human result for inositol is 1.79 times the chance of a regular menstrual cycle vs placebo in a 2023 meta-analysis of 26 trials (1,691 women). The headline human result for metformin is observational only: diabetics on metformin survived as long as matched non-diabetics; the TAME outcome trial has not reported.

Key studies behind each

Inositol

  1. Croze ML, Soulage CO. (2013). Potential role and therapeutic interests of myo-inositol in metabolic diseases. Biochimie. PubMed 23764390
  2. Keenan JM. (2013). Wax-matrix extended-release niacin vs inositol hexanicotinate: a comparison of wax-matrix, extended-release niacin to inositol hexanicotinate "no-flush" niacin in persons with mild to moderate dyslipidemia. J Clin Lipidol. PubMed 23351578
  3. Vucenik I, Druzijanic A, Druzijanic N. (2020). Inositol Hexaphosphate (IP6) and Colon Cancer: From Concepts and First Experiments to Clinical Application. Molecules. PubMed 33333775
  4. Carlomagno G, Unfer V, Roseff S. (2011). The D-chiro-inositol paradox in the ovary. Fertil Steril. PubMed 21641593

Metformin

  1. Bannister CA, Holden SE, Jenkins-Jones S, et al. (2014). Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls. Diabetes Obes Metab. PubMed 25041462
  2. Kulkarni AS, Gubbi S, Barzilai N. (2020). Benefits of Metformin in Attenuating the Hallmarks of Aging. Cell Metab. PubMed 32333835
  3. Kulkarni AS, Brutsaert EF, Anghel V, et al. (2018). Metformin regulates metabolic and nonmetabolic pathways in skeletal muscle and subcutaneous adipose tissues of older adults (MILES). Aging Cell. PubMed 29383869
  4. Barzilai N, Crandall JP, Kritchevsky SB, et al. (2016). Metformin as a Tool to Target Aging. Cell Metab. PubMed 27304507

The full evidence reviews

Related comparisons